NCT05862285 2026-03-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
Clinical Trials
42 trialsNCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT03833167 2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT05377554 2026-02-27
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
Phase 3 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05303532 2026-02-23
ROSY-D
AstraZeneca
Phase 3 Enrolling by invitation
NCT07023315 2026-02-11
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Phase 3 Recruiting
NCT06127407 2026-02-06
CHONQUER
Servier
Phase 3 Recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03148418 2026-01-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05112965 2026-01-07
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05629234 2025-12-24
ROSY-T
AstraZeneca
Phase 3 Active not recruiting
NCT04464226 2025-11-06
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Recruiting
NCT06867705 2025-08-01
RC-102
Resilience
Phase 3 Recruiting
NCT06961188 2025-05-07
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT05261399 2025-01-10
SAFFRON
AstraZeneca
Phase 3 Recruiting
NCT03764293 2024-02-06
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03952403 2023-08-08
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT04033354 2023-08-08
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
Shanghai Henlius Biotech
Phase 3 Unknown
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT00625378 2022-09-01
STEP
Bayer
Phase 3 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed
NCT02453334 2021-05-11
IRON CLAD
American Regent, Inc.
Phase 3 Completed
NCT03811418 2019-11-26
ATTILA
iOMEDICO AG
Phase 3 Withdrawn
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT02125240 2018-07-16
ICWIP
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT00548548 2017-06-14
AVAGAST
Genentech, Inc.
Phase 3 Completed
NCT02721641 2017-03-31
A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01145638 2015-12-03
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
Pharmacosmos A/S
Phase 3 Completed
NCT01011751 2015-07-30
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Takeda
Phase 3 Completed
NCT01050829 2014-12-30
Gadobutrol Magnevist-controlled Body Study
Bayer
Phase 3 Completed
NCT01429051 2014-03-26
NOSE-400
Takeda
Phase 3 Completed
NCT00135317 2013-05-23
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
Amgen
Phase 3 Completed
NCT00362583 2012-05-07
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Nycomed
Phase 3 Completed
NCT01168206 2011-09-09
Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy
Lavilabor Natural Products Ltd
Phase 3 Unknown
NCT00140075 2011-05-26
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Pfizer
Phase 3 Completed
NCT00635973 2009-04-22
Open-Label Extension of Other SZ1839 (Iressa) Trials
AstraZeneca
Phase 3 Completed
NCT00539630 2007-10-04
TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN
Sanofi
Phase 3 Completed